InsiderPulse
← 10-K / 10-Q
10-QTRAW

Traws Pharma, Inc.

Filed 2026-05-15Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
Revenue$57K+0.0%
R&D Expense$4.9M+96.0%
SG&A Expense$2.0M-26.1%
Operating Income-$6.9M-33.5%
Net Income-$7.1M-133.1%
EPS (Basic)-$0.53-124.4%
EPS (Diluted)-$0.53-125.4%

Balance Sheet

Line Item2026-03-31Q/QY/Y
Accounts Receivable$1.7M-55.5%+2.0%
Current Assets$5.7M-29.0%-70.0%
Total Assets$8.2M-23.2%-57.2%
Current Liabilities$13.2M+18.5%+27.0%
Total Liabilities$13.5M+19.7%+3.1%
Stockholders' Equity-$5.3M-744.4%-188.5%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$2.6M+52.6%
Financing Cash Flow$1.9M